Finch Therapeutics is a biotechnology company focused on developing microbiome-based therapeutics. The company operates in the healthcare and pharmaceutical market, targeting conditions such as recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and autism-related gastrointestinal symptoms. Finch's unique approach involves utilizing data from human interventional studies and a machine learning-based platform to understand the microbiome communities that drive positive clinical outcomes. This 'Human First' discovery platform allows Finch to start drug development with a clinical understanding rather than a purely laboratory-based approach. The business model primarily revolves around research and development, clinical trials, and partnerships with other pharmaceutical companies. Finch generates revenue through the development and commercialization of its therapeutic products, as well as through collaborations and licensing agreements. The company's clients include healthcare providers, patients, and pharmaceutical partners.

Keywords: microbiome, therapeutics, C. difficile, hepatitis B, inflammatory bowel, autism, clinical trials, machine learning, drug development, healthcare.